Rahman P, et al. - This trial elucidated the minimal disease activity (MDA) rate over time in patients with psoriatic arthritis (PsA) receiving antitumour necrosis factor agents. In addition, it gauged the prognostic factors of MDA achievement and determined the most common unmet criteria among MDA achievers. Approximately 50% of patients treated with infliximab (IFX) or golimumab (GLM) in routine clinical care achieved MDA within the first year of therapy. Lower baseline Health Assessment Questionnaire (HAQ) and lower TJC28, served as vital prognostic factors of MDA achievement. The most commonly unmet criteria in patients who achieved MDA were found to be the pain, patient’s global assessment (PtGA) and Psoriasis Area and Severity Index (PASI).